LCD-L33445
Document details
Summary
The implementation of the LCD for the removal of benign and malignant skin lesions by Palmetto GBA may affect billing practices starting from October 23, 2025. Providers will need to ensure complianceNew LCD impacts skin lesion removal billing practices.
Affected codes
ICD-10-CM
Affected specialty
Dermatology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33445&ver=79CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761262 · Dermatology
SKYRIZI (risankizumab-rzaa) is an injectable drug approved for use under Medicare Part B, likely leading to the assignment of a new J-code for billing purposes. As an orphan drug in the interleukin-23
View alertPolicy FDA-BLA761105 · Dermatology
SKYRIZI (Risankizumab-rzaa), being an injectable drug approved under the BLA, is likely to be assigned a J-code for Medicare billing. Given its classification as an orphan drug and its high cost, pass
View alertPolicy FDA-NDA019835 · Dermatology
CETIRIZINE HYDROCHLORIDE, marketed as ZYRTEC HIVES, is an oral drug and will be billed under Medicare Part D. Given that it is not an injectable drug, no J-code will be assigned, and typical reimburse
View alertPolicy FDA-NDA021951 · Dermatology
As ABSORICA (isotretinoin) is an oral drug, it will be billed under Medicare Part D. Given that it is a medication used for severe acne, prescribers should consider any prior authorizations or step th
View alert